After 30 years of use in transplant medicine, EBV-specific T cells offer key lessons for safer, scalable allogeneic cell therapies, writes Ivan Horak, M.D.

On this weeks episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to ...

On this weeks episode of the Business of Biotech, Philina Lee, Ph.D., CEO at AdvanCell, explains how lead-based targeted alpha therapies can unlock deeper, more durable cancer responses, and why ...

Servant leadership means putting people first because results follow people, not the other way around, writes Boehringer ...

A company launching a drug in the United States in 2027 will hire its contract sales organization (CSO) from a market that has changed since its executives last bought from it. Five of the best-known ...

Co-development is an established concept. The practical question is how early its logic should shape candidate selection, development planning, and portfolio governance. Combination therapy is routine ...

In pharma, an oncology drug approval is a significant milestone. I have spent enough time in this space to know that it is also the moment where a different, less visible problem begins. The community ...

The choice between Nasdaq and the New York Stock Exchange (or NYSE American) has traditionally been made once – and rarely revisited. Market perception, investor demographics, analyst coverage, ...

Life sciences companies operate at the leading edge of innovation, structuring high-value licensing, development, and outsourcing arrangements in a highly regulated environment. A persistent and often ...

"The pioneer spirit is still vigorous within this nation. Science offers a largely unexplored hinterland for the pioneer who has the tools for his task. Scientific progress is one essential key to our ...

Bouncing around the San Diego Convention Center’s 2.6 million square feet for four days is its own kind of flustery exercise, but in the age of Zoom it’s a more-than-welcome excursion. It’s hard to ...

Individualized genetic medicine is moving faster than the traditional drug approval model was built to handle. Genome editing, RNA-based medicines, and other targeted therapies can now be designed for ...